Clinical Trial Update: Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study evaluating daclatasvir with sofosbuvir and ribavirin for 12 or 16 weeks in genotype 3 chronic hepatitis C with advanced fibros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daklinza (Daclatasvir)
• Ribavirin (ribavirin)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2017-01-27